- Sector
- Healthcare
- Industry
- Biotechnology
Highlights
- Market Cap
- $1.85B
- Enterprise Value
- $1.79B
- EPS (TTM)
- $7.42
- PE Ratio
- 3.78
- Total Revenue (TTM)
- $1.04B
- Gross Profit (TTM)
- $1.02B
- EBITDA (TTM)
- $398.09M
- Year Range
- $26.42 - $37.78
- ROA (TTM)
- 14.49%
- ROE (TTM)
- 15.02%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LKFT Performance Chart
Lakefront Biotherapeutics NV (LKFT) is down 14.3% since the beginning of the year. At $28 per share, LKFT is trading 25.8% below its 52-week high of $38. Investors who bought $1,000 worth of LKFT shares 5 years ago would now be looking at an investment worth $380.
Loading charts...
Returns By Period
Lakefront Biotherapeutics NV (LKFT) has returned -14.31% so far this year and 0.21% over the past 12 months. Over the last ten years, LKFT has returned -6.92% per year, falling short of the S&P 500 Index benchmark, which averaged 13.33% annually.
Lakefront Biotherapeutics NV
- 1D
- -0.32%
- 1M
- -2.74%
- YTD
- -14.31%
- 6M
- -11.30%
- 1Y
- 0.21%
- 3Y*
- -12.90%
- 5Y*
- -17.58%
- 10Y*
- -6.92%
Benchmark (S&P 500 Index)
- 1D
- -2.64%
- 1M
- 0.25%
- YTD
- 7.86%
- 6M
- 7.47%
- 1Y
- 24.32%
- 3Y*
- 19.90%
- 5Y*
- 11.79%
- 10Y*
- 13.33%
LKFT Monthly Returns History
Based on dividend-adjusted daily data since May 14, 2015, LKFT's average daily return is +0.01%, while the average monthly return is +0.21%. At this rate, an investment would double in approximately 27.5 years.
Historically, 43% of months were positive and 57% were negative. The best month was Jul 2019 with a return of +34.5%, while the worst month was Sep 2015 at -32.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, LKFT closed higher 49% of trading days. The best single day was Mar 29, 2019 with a return of +22.5%, while the worst single day was Sep 25, 2015 at -27.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.61% | -0.65% | -10.87% | -7.23% | 1.87% | -1.16% | -14.31% | ||||||
| 2025 | -16.36% | 13.39% | -3.68% | 7.17% | 6.84% | -2.68% | 17.26% | -4.20% | 10.18% | -8.26% | -1.45% | 4.41% | 18.91% |
| 2024 | -7.58% | -6.55% | -8.29% | -11.65% | -2.21% | -10.93% | 7.63% | 9.19% | -1.13% | -8.16% | 4.54% | -0.51% | -32.35% |
| 2023 | -0.47% | -15.13% | 3.08% | 0.93% | 6.05% | -1.69% | 4.16% | -10.53% | -8.81% | -3.21% | 11.93% | 8.60% | -8.40% |
| 2022 | 22.44% | -1.88% | -6.36% | -6.19% | -5.45% | 1.44% | -8.76% | -1.67% | -14.82% | 6.80% | -12.67% | 11.59% | -19.50% |
| 2021 | 5.37% | -20.81% | -6.67% | 0.88% | -2.10% | -9.52% | -12.12% | -2.84% | -10.56% | 0.72% | -8.32% | 13.48% | -44.30% |
Benchmark Metrics
Lakefront Biotherapeutics NV has an annualized alpha of -7.06%, beta of 0.79, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since May 15, 2015.
- This stock participated in 88.66% of S&P 500 Index downside but only 26.06% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.06%
- Beta
- 0.79
- R²
- 0.12
- Upside Capture
- 26.06%
- Downside Capture
- 88.66%
Return for Risk
Risk / Return Rank
LKFT ranks 40 for risk / return — below 40% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Lakefront Biotherapeutics NV (LKFT) and compare them to S&P 500 Index.
| LKFT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.00 | ||
| Sortino ratioReturn per unit of downside risk | -2.50 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.36 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | 0.01 | 2.69 | -2.68 |
| Martin ratioReturn relative to average drawdown | 0.01 | 12.34 | -12.33 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lakefront Biotherapeutics NV. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lakefront Biotherapeutics NV was 91.72%, occurring on Feb 4, 2025. The portfolio has not yet recovered.
The current Lakefront Biotherapeutics NV drawdown is 89.77%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -91.72%Feb 2025 | 4y 11mo | — | 6y 3moFeb 2020 - now |
2016 bear market2016 | -40.67%Feb 2016 | 5mo 22d | 7mo 13d | 1y 1moAug 2015 - Sep 2016 |
Rate-hike selloffLate 2018 | -26.96%Dec 2018 | 10mo 28d | 3mo 10d | 1y 2moJan 2018 - Apr 2019 |
2019 bear market2019 | -22.13%Oct 2019 | 2mo 11d | 1mo | 3mo 11dJul 2019 - Nov 2019 |
2017 bear market2017 | -20.81%Aug 2017 | 3mo 23d | 22d | 4mo 15dApr 2017 - Aug 2017 |
Drawdown Indicators
| LKFT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.72% | -56.78% | -34.94% |
Max Drawdown (1Y)Largest decline over 1 year | -29.27% | -9.10% | -20.17% |
Max Drawdown (3Y)Largest decline over 3 years | -47.28% | -18.90% | -28.38% |
Max Drawdown (5Y)Largest decline over 5 years | -71.87% | -25.43% | -46.44% |
Max Drawdown (10Y)Largest decline over 10 years | -91.72% | -33.92% | -57.80% |
Current DrawdownCurrent decline from peak | -89.77% | -2.97% | -86.80% |
Average DrawdownAverage peak-to-trough decline | -49.38% | -10.72% | -38.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.49% | 1.97% | +12.52% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lakefront Biotherapeutics NV over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lakefront Biotherapeutics NV is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for LKFT, comparing it with other companies in the Biotechnology industry. Currently, LKFT has a P/E ratio of 3.8. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LKFT relative to other companies in the Biotechnology industry. Currently, LKFT has a P/S ratio of 1.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LKFT in comparison with other companies in the Biotechnology industry. Currently, LKFT has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LKFT
Add Lakefront Biotherapeutics NV to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LKFT